MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

355.20 +1.14 (+0.32%)
Official Closing Price Updated: 4:15 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
66 67 Next >
News headline image
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival ↗
The results are also promising for the next-generation version of that drug. 
Via Investor's Business Daily
News headline image
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters. ↗
The current leadership in the stock market is clearly not tech, or the Magnificent 7. 
Via Talk Markets
News headline image
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern ↗
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
News headline image
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
News headline image
(AMGN) - Analyzing Amgen's Short Interest ↗
 
Via Benzinga
News headline image
Amgen Unusual Options Activity For August 29 ↗
 
Via Benzinga
News headline image
Smart Money Is Betting Big In AMGN Options ↗
 
Via Benzinga
News headline image
Amgen Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
Patchy But Still Bullish ↗
Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations. 
Via Talk Markets
News headline image
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
News headline image
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades' ↗
Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on guidance. 
Via Benzinga
News headline image
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
News headline image
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
News headline image
3 Unstoppable Dividend Stocks to Buy Right Now ↗
These stocks are the A-team for income investors. 
Via The Motley Fool
News headline image
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks ↗
The gravity-defying climb faces risk, as the index futures trade narrowly mixed in early trading on Tuesday. That said, the recent gains could keep traders wary of a potential pullback. 
Via Benzinga
Topics Stocks
News headline image
ProInvestor Insights - August 2024 ↗
Our August newletter features insights from high-level Wall Street researchers, traders, analysts, and economists that you won’t find anywhere else. And AAII’s first-to-be-seen interview with legendary... 
Via Talk Markets
News headline image
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade ↗
Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average. 
Via The Motley Fool
Topics Stocks
News headline image
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline ↗
Amgen has many growth opportunities ahead, and it also pays a fairly high dividend. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations ↗
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
News headline image
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
News headline image
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
News headline image
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal ↗
The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture. 
Via Talk Markets
Topics Stocks
News headline image
Here's Why Eli Lilly Stock Dropped 12% Last Month ↗
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
News headline image
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts ↗
Amgen posted mixed Q2 results. Analysts highlight upcoming clinical readouts in obesity and inflammatory disease as crucial. Despite some underperformance, growth prospects remain strong, with... 
Via Benzinga
News headline image
Why Amgen Stock Is Down Today Despite Solid Q2 Results ↗
Shares may have been likely to fall no matter what the company reported. 
Via The Motley Fool
News headline image
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst ↗
Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and... 
Via Benzinga
News headline image
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
News headline image
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday? ↗
The U.S. 
Via Benzinga
News headline image
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story